ReWalk Robotics Reports Second Quarter 2016 Financial Results --Placed 24 Personal Units, 18 of which were covered by insurance-- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA

ReWalk Robotics Reports Second Quarter

2016 Financial Results

--Placed 24 Personal Units, 18 of which were covered by insurance--

ILIT, ISRAEL / MARLBOROUGH, MA, August 4, 2016 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or

"the Company") today announced its financial results for the three- and six-month periods ended June 30, 2016.

Highlights of and subsequent to the second quarter include:

"As ReWalk's technology

and the benefits of exoskeleton use become increasingly accepted, ReWalk is uniquely positioned to remain the global leader in

developing and marketing exoskeletons for lower limb disabilities," stated Larry Jasinski,

Chief Executive Officer.

"A record number of personal

units were placed with customers, of which 75% were covered by insurance reimbursement. Our extensive efforts to support the VA

continue to drive our commercialization activities, with seven centers across the U.S. now operating as ReWalk training facilities,

allowing us to reach a broader universe of veterans. We continue to gain traction in Europe, with yet another German court approving

reimbursement on appeal, ruling that the ReWalk exoskeleton is medically necessary. Importantly, we believe our new collaboration

with Harvard's Wyss Institute will, in time, help fill the need for soft wearable exoskeleton suits designed to support individuals

affected by stroke, MS, Parkinson's and senior citizens who require mobility assistance," he added.

ReWalk Robotics Reports Second Quarter 2016 Financial Results

"While we believe that these

elements, taken together, will allow ReWalk to remain the global leader in exoskeleton technology addressing a broad range of lower

limb disabilities, we are adjusting our expectations on the timing of top line growth for the balance of 2016. Based on the increase

in rental units during the second quarter, we believe a portion of our revenue dollars have shifted to subsequent periods, and

we are providing top line guidance of approximately $1.3 million for the third quarter of 2016 and a range of $6.2 million to $7.0

million for the full year," concluded Jasinski.

Second Quarter 2016 Financial

Total revenue was $817,000 for the

second quarter of 2016, an increase of 34%, compared with $610,000 in the second quarter of 2015. 25 ReWalk systems were placed

during the second quarter, compared with 12 ReWalk systems placed in the prior year period and 32 placed in the first quarter of

2016. 16 were rental units, including 6 units placed through the VA as part of its coverage policy. The increase in rental units

during the quarter was driven by commercial insurance payers in Germany and units placed with veterans under the VA policy. At

the end of the second quarter, rental units represented $1.1 million in potential revenue backlog.

expense was $3.1 million for the second quarter of 2016, compared to $1.5 million during the same period last year, reflecting

costs of increased investment in product development programs and clinical activities and a one-time charge related to ReWalk's

collaboration agreement with the Wyss Institute at Harvard University.

SG&A expense grew to $5.6 million

for the second quarter of 2016, compared to $4.5 million in the prior year period, primarily reflecting investment in reimbursement

Net loss was $9.1 million for the second

quarter of 2016 compared with a net loss of $5.8 million in the prior year quarter. Non-GAAP net loss for the second quarter was

$8.0 million compared with a non-GAAP net loss of $5.1 million in the second quarter of 2015.

A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

As of June 30, 2016, ReWalk had $15.7

million in cash and cash equivalents.

Based on the increase in rental unit

placements during the second quarter, we believe a portion of our revenue dollars have shifted to subsequent quarters, and as a

result we are providing top line guidance of approximately $1.3 million for the third quarter of 2016 and a range of $6.2 million

to $7.0 million for the full year. The timing of certain key business catalysts during the second half of 2016, such as placements

in our international markets, timing of reimbursement decisions, rental unit conversions and larger orders to support the VA research

study may shift from quarter to quarter.

ReWalk management will host its second

quarter conference call as follows:

ReWalk Robotics Reports Second Quarter 2016 Financial Results

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 54201193.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury.

Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and

development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.

For more information on the ReWalk systems, please visit http://www.rewalk.com.

is a registered trademark of ReWalk Robotics Ltd. in Israel.

Forward-Looking Statements

addition to historical information, this press release contains forward-looking statements within the meaning of the U.S.

Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S.

Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future

performance and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should,"

"would," "seek" and similar terms or

phrases. The forward-looking statements contained in this press release are based on management's current expectations,

which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are

outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from

those indicated in the forward-looking statements include, among others: ReWalk's expectations regarding future growth,

including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk's

ability to maintain and grow its reputation and to achieve and maintain market acceptance of its products; ReWalk's

ability to achieve reimbursement from third-party payors for its products; ReWalk's expectations as to its clinical

research program and clinical results; ReWalk's

expectations as to the results of, and the Food and Drug Administration's

potential regulatory actions with respect to, ReWalk's

mandatory post-market 522 surveillance study; ReWalk's ability to repay its secured indebtedness; ReWalk's

ability to improve its products and develop new products; ReWalk's ability to maintain adequate protection of its

intellectual property and to avoid violation of the intellectual property rights of others; ReWalk's ability to gain

and maintain regulatory approvals; ReWalk's ability to

secure capital from its at-the-market equity distribution program based on the price range of its ordinary shares and

conditions in the financial markets; ReWalk's ability to maintain relationships with existing customers and develop

relationships with new customers; and other factors discussed under the heading "Risk Factors" in

ReWalk's Annual Report on Form 10-K for the year ended December 31, 2015 filed with the U.S. Securities and Exchange

Commission and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any

forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause

ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not

possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any

forward-looking statements, whether as a result of new information, future developments or otherwise.

ReWalk Robotics Reports Second Quarter 2016 Financial Results

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are

prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of

non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers

to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three and six months ended June 30, 2016 and

2015, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense,